山东鲁抗医药集团赛特有限责任公司
Clinical Trials
0
Active:0
Completed:0
Trial Phases
0 Phases
Drug Approvals
154
NMPA:154
Drug Approvals
Moxifloxacin Hydrochloride and Sodium Chloride Injection
- Product Name
- 盐酸莫西沙星氯化钠注射液
- Approval Number
- 国药准字H20249030
- Approval Date
- Oct 9, 2024
NMPA
Dapoxetine Hydrochloride Tablets
- Product Name
- 盐酸达泊西汀片
- Approval Number
- 国药准字H20244308
- Approval Date
- Jun 28, 2024
NMPA
Dapoxetine Hydrochloride Tablets
- Product Name
- 盐酸达泊西汀片
- Approval Number
- 国药准字H20244309
- Approval Date
- Jun 28, 2024
NMPA
Phloroglucinol Injection
- Product Name
- 间苯三酚注射液
- Approval Number
- 国药准字H20243721
- Approval Date
- May 15, 2024
NMPA
Pefloxacin Mesylate Capsules
- Product Name
- 甲磺酸培氟沙星胶囊
- Approval Number
- 国药准字H20093679
- Approval Date
- May 11, 2024
NMPA
- Prev
- 1
- 2
- 3
- 4
- 5
- 16
- Next
Clinical Trials
No trials found
News
No news found